Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with paritaprevir-ritonavir and ombitasvir

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 2, 2016, Pages 1106-1113

  Krishnan, Preethi ^a   Schnell, Gretja ^a   Tripathi, Rakesh ^a   Beyer, Jill ^a   Reisch, Thomas ^a   Zhang, Xinyan ^a   Setze, Carolyn ^a   Rodrigues, Lino ^a   Burroughs, Margaret ^a   Redman, Rebecca ^a   Chayama, Kazuaki ^b   Kumada, Hiromitsu ^c   Collins, Christine ^a   Pilot Matias, Tami ^a  

^a ABBVIE INC   (United States)

^b HIROSHIMA UNIVERSITY   (Japan)

^c TORANOMON HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5A; OMBITASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; PARITAPREVIR PLUS RITONAVIR; RITONAVIR; UNCLASSIFIED DRUG; ABT-267; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; EC50; FOLLOW UP; GENE FREQUENCY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1B; HUMAN; IN VITRO STUDY; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; TREATMENT RESPONSE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; HEPACIVIRUS; JAPAN; PATHOGENICITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POPULATION GENETICS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIROLOGY;

ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENETICS, POPULATION; HEPACIVIRUS; HEPATITIS C; HUMANS; JAPAN; MACROCYCLIC COMPOUNDS; POLYMORPHISM, GENETIC; RITONAVIR; TREATMENT FAILURE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84957899900     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02606-15     Document Type: Article

References (34)

1. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107-115. http://dx.doi.org/10.1111/j.1469-0691.2010.03432.x.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333-1342. http://dx.doi.org/10.1002/hep.26141.
3. Chung H, Ueda T, Kudo M. 2010. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 53:39-43. http://dx.doi.org/10.1159/000252782.
4. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. Hepatology 59:318-327. http://dx.doi.org/10.1002/hep.26744.
5. Takada A, Tsutsumi M, Okanoue T, Matsushima T, Komatsu M, Fujiyama S. 1996. Distribution of the different subtypes of hepatitis C virus in Japan and the effects of interferon: a nationwide survey. J Gastroenterol Hepatol 11:201-207. http://dx.doi.org/10.1111/j.1440-1746.1996.tb00063.x.
6. Tanaka Y, Kurbanov F, Mano S, Orito E, Vargas V, Esteban JI, Yuen MF, Lai CL, Kramvis A, Kew MC, Smuts HE, Netesov SV, Alter HJ, Mizokami M. 2006. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 130:703-714. http://dx.doi.org/10.1053/j.gastro.2006.01.032.
7. Simmonds P. 2004. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85:3173-3188. http://dx.doi.org/10.1099/vir.0.80401-0.
8. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, Simmonds P. 1997. The origin of hepatitis C virus genotypes. J Gen Virol 78(Part 2):321-328. http://dx.doi.org/10.1099/0022-1317-78-2-321.
9. Simmonds P. 1995. Variability of hepatitis C virus. Hepatology 21:570-583. http://dx.doi.org/10.1002/hep.1840210243.
10. McCloskey RM, Liang RH, Joy JB, Krajden M, Montaner JS, Harrigan PR, Poon AF. 2015. Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism. J Infect Dis 211:1288-1295.
11. Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, Reisch T, Irvin M, Hopkins T, Pithawalla R, Middleton T, Ng T, McDaniel K, Or YS, Menon R, Kempf D, Molla A, Collins C. 2015. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 59:988-997. http://dx.doi.org/10.1128/AAC.04227-14.
12. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, Kati W, Campbell A, Williams L, Xie W, Setze C, Molla A, Collins C, Pilot-Matias T. 2015. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 59:979-987. http://dx.doi.org/10.1128/AAC.04226-14.
13. Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L, Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Kumada H. 2015. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology 61:1523-1532. http://dx.doi.org/10.1002/hep.27705.
14. Kumada H, Chayama K, Rodrigues L, Jr, Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka K, Setze C, Pilot-Matias T, Patwardhan M, Vilchez RA, Burroughs M, Redman R. 2015. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for HCV genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 62:1037-1046. http://dx.doi.org/10.1002/hep.27972.
15. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo H, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M. 2015. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 15:645- 653. http://dx.doi.org/10.1016/S1473-3099( 15)70099-X.
16. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. 2014. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59:2083-2091. http://dx.doi.org/10.1002/hep.27113.
17. Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, Miller MD, Mo H. 2013. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 57:6333-6340. http://dx.doi.org/10.1128/AAC.02193-12.
18. Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H. 2013. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 58:646-654. http://dx.doi.org/10.1016/j.jhep.2012.11.012.
19. Gilead Sciences International Ltd. 2015. Harvoni (ledipasvir and sofosbuvir tablets). Summary of product characteristics. Gilead Sciences International Ltd., Cambridge, United Kingdom.
20. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Mullhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L, Jr, Hu YB, Podsadecki T, Bernstein B. 2014. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147:359-365. http://dx.doi.org/10.1053/j.gastro.2014.04.045.
21. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. 2014. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370:1973-1982. http://dx.doi.org/10.1056/NEJMoa1402869.
22. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. 2014. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1604-1614. http://dx.doi.org/10.1056/NEJMoa1401561.
23. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. 2014. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1594-1603. http://dx.doi.org/10.1056/NEJMoa1315722.
24. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, Podsadecki T, Bernstein B. 2014. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 370:222-232. http://dx.doi.org/10.1056/NEJMoa1306227.
25. Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, Xie W, Larsen L, Cohen D, Podsadecki T, Pilot-Matias T, Collins C. 2015. Resistance analysis of baseline and treatment-emergent variants in the AVIATOR study with paritaprevir/r, ombitasvir and dasabuvir in HCV genotype 1. Antimicrob Agents Chemother 59:5445-5454. http://dx.doi.org/10.1128/AAC.00998-15.
26. Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S. 2015. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385:2502-2509. http://dx.doi.org/10.1016/S0140-6736( 15)60159-3.
27. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. 2014. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370:1983-1992. http://dx.doi.org/10.1056/NEJMoa1402338.
28. Combet C, Garnier N, Charavay C, Grando D, Crisan D, Lopez J, Dehne-Garcia A, Geourjon C, Bettler E, Hulo C, Le Mercier P, Bartenschlager R, Diepolder H, Moradpour D, Pawlotsky JM, Rice CM, Trepo C, Penin F, Deleage G. 2007. euHCVdb: the European hepatitis C virus database. Nucleic Acids Res 35:D363-D366. http://dx.doi.org/10.1093/nar/gkl970.
29. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S. 2014. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384:1597- 1605. http://dx.doi.org/10.1016/S0140-6736( 14)61059-X.
30. Kieffer TL, George S. 2014. Resistance to hepatitis C virus protease inhibitors. Curr Opin Virol 8:16-21. http://dx.doi.org/10.1016/j.coviro.2014.04.008.
31. Middleton T, He Y, Pilot-Matias T, Tripathi R, Lim BH, Roth A, Chen CM, Koev G, Ng TI, Krishnan P, Pithawalla R, Mondal R, Dekhtyar T, Lu L, Mo H, Kati WM, Molla A. 2007. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations. J Virol Methods 145:137-145. http://dx.doi.org/10.1016/j.jviromet.2007.05.016.
32. Tripathi RL, Krishnan P, He Y, Middleton T, Pilot-Matias T, Chen CM, Lau DT, Lemon SM, Mo H, Kati W, Molla A. 2007. Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera. Antiviral Res 73:40-49. http://dx.doi.org/10.1016/j.antiviral.2006.07.005.
33. DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, Mistry N, Koev G, Reisch TJ, Mondal R, Pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins C, Wagner R, Kati WM. 2014. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem 57:2047-2057. http://dx.doi.org/10.1021/jm401398x.
34. Sarrazin C, Lathouwers E, Peeters M, Daems B, Buelens A, Witek J, Wyckmans Y, Fevery B, Verbinnen T, Ghys A, Schlag M, Baldini A, De Meyer S, Lenz O. 2015. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res 116:10-16. http://dx.doi.org/10.1016/j.antiviral.2015.01.003.